3d185
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2019 (NCT04221204)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05039892 | Phase 2 | Jun 30, 2022 | 3D Medicines |
| NCT04221204 | Phase 1 | Sep 1, 2019 | 3D Medicines |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 3D Medicines | For profit | 2 | 2 | 2 | 2019 |
1 organizations
Page 1 / 1